Stock MGX METAGENOMI, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Metagenomi, Inc.

Equities

MGX

US59102M1045

Real-time Estimate Cboe BZX
Other stock markets
 07:27:12 18/06/2024 pm IST 		5-day change 1st Jan Change
4.255 USD +1.07% Intraday chart for Metagenomi, Inc. -31.67% 0.00%
14/05 Metagenomi, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
07/05 HC Wainwright Starts Metagenomi With Buy Rating, $10 Price Target MT

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
METAGENOMI, INC. Stock Metagenomi, Inc.
0.00% 16Cr - -
MODERNA, INC. Stock Moderna, Inc.
+35.06% 5.28TCr
B-
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-7.24% 3.89TCr
B
LONZA GROUP AG Stock Lonza Group AG
+35.48% 3.82TCr
A
CELLTRION, INC. Stock Celltrion, Inc.
-10.77% 2.68TCr
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.92% 2.62TCr
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-18.12% 1.99TCr
B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+36.71% 1.32TCr
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.39% 1.22TCr
C+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-2.67% 1.18TCr
B+
Investor Rating
-
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
-
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. MGX Stock
  4. Ratings Metagenomi, Inc.